article thumbnail

Oncotarget: A novel format for recombinant antibody-interleukin-2 fusion proteins

Scienmag

Oncotarget recently published a novel format for recombinant antibody-interleukin-2 fusion proteins exhibits superior tumor-targeting properties in vivo which reported that here, the authors describe four novel formats for the L19-IL2 fusion Credit: Correspondence to – Dario Neri – dario.neri@pharma.ethz.ch

article thumbnail

Salk team reveals never-before-seen antibody binding, informing liver cancer, antibody design

Scienmag

Multi-institute collaboration uses X-ray crystallography and recombinant antibodies to uncover workings of an elusive molecule central to human health Credit: Salk Institute LA JOLLA–(February 17, 2021) In structural biology, some molecules are so unusual they can only be captured with a unique set of tools.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

New anti-evolocumab antibodies could aid drug development

Drug Discovery World

Bio-Rad Laboratories has introduced a range of type 1 antibodies that inhibit the binding of evolocumab (Repatha) to its target, human proprotein convertase subtilisin/kexin type 9 (PCSK9), a protein that has been shown to play a key role in the regulation of cholesterol levels. .

article thumbnail

Transgene and BioInvent Receive Approval From ANSM to Proceed With Phase I/IIa Trial of Anti-CTLA4-armed Oncolytic Virus BT-001 in Solid Tumors

The Pharma Data

From this, BT-001 is engineered to encode both a highly differentiated Treg depleting anti-CTLA4 antibody and the human GM-CSF cytokine. The recombinant antibody recognizing human CTLA4 was generated by BioInvent’s proprietary n-CoDeR®/F.I.R.S.T

Trials 40
article thumbnail

What to expect from PEGS Europe 2023: Day 2

Drug Discovery World

The luncheon presentations include: Matthias Hillenbrand, PhD, Head, Infectious Disease Research & Biosafety Officer, Memo Therapeutics, on: ‘Best in class antiviral antibodies from cognate recombinant antibody repertoires of human donors’.